Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. News
  3. cancer cell
Show results for
Products
Services
Software
Applications

Companies

News
Articles
Books
Downloads
Videos

Refine by
Date

  • This Year
  • Older

Cancer Cell Articles & Analysis

393 news found

CD Bioparticles Launches Advanced Bio-Targeted Small Molecules Conjugated Magnetic Nanoparticles for Targeted Cancer Therapy

CD Bioparticles Launches Advanced Bio-Targeted Small Molecules Conjugated Magnetic Nanoparticles for Targeted Cancer Therapy

These molecules can bind to targets highly expressed on cancer cell surfaces and be targeted during drug delivery. For example, folic acid (folates) can be used. Cancer and embryonic cells preferentially use the folate receptor (FR), which has a high affinity for folic acid (K_d = 1–10nM) and can uptake folic acid via ...

ByCD Bioparticles


Accepting new applications for ACE program 2025

Accepting new applications for ACE program 2025

Following the generation of successful results with the University of Michigan through the ACE program, Predictive Oncology is now actively calling for submissions for a new cohort of compounds to be tested in Q4 2025. ACE program participation is offered exclusively to academic institutions and provides access to the POAI proprietary active ML/AI and biobank of primary patient ...

ByPredictive Oncology Inc.


Protheragen-ING Releases Hundreds of APIs: Anti-Tumor APIs, Hypoglycemic APIs, Antipsychotic APIs, Bronchiectasis APIs, Antihypertensive APIs

Protheragen-ING Releases Hundreds of APIs: Anti-Tumor APIs, Hypoglycemic APIs, Antipsychotic APIs, Bronchiectasis APIs, Antihypertensive APIs

Expanding the Horizon with Advanced Anti-Tumor APIs Protheragen-ING’s new anti-tumor APIs are a quantum leap forward for cancer therapy. Such APIs come in a wide range of types: chemotherapeutic, targeted, immunotherapeutic, hormone therapeutic. The APIs in chemotherapy work by interfering with the cell division mechanism to suppress cancer ...

ByProtheragen-ING


Tethis S.p.A. Collaborates with Weill Cornell Medicine to Advance Cellular Residual Disease Monitoring in Early-Stage Breast Cancer

Tethis S.p.A. Collaborates with Weill Cornell Medicine to Advance Cellular Residual Disease Monitoring in Early-Stage Breast Cancer

As part of the collaboration, Tethis has placed one of its automated See.d instruments in the Cristofanilli lab, and the lab will use the instrument to isolate plasma and prepare cytology slides containing cells, including circulating tumor cells, from the blood. The Cristofanilli lab will analyze the isolated plasma samples for cell-free DNA ...

ByTethis S.p.A


CD Formulation Is A Reliable Provider of Customized Drug Conjugates Services

CD Formulation Is A Reliable Provider of Customized Drug Conjugates Services

In the rapidly evolving landscape of pharmaceutical innovations, CD Formulation emerges as a key player, offering customized drug conjugates services that cater to the rising demands for advanced drug development. Specializing in complex biologic formulations, Biologics & Biosimilars service team of CD Formulation is revolutionizing how drug conjugate products are conceptualized and produced, ...

ByCD Formulation


SOPHiA GENETICS Presents Ground-Breaking Multimodal Research on AI-Driven Patient Stratification at ESMO 2024

SOPHiA GENETICS Presents Ground-Breaking Multimodal Research on AI-Driven Patient Stratification at ESMO 2024

The study, conducted in collaboration with AstraZeneca, leverages advanced AI-driven techniques to identify subgroups of stage IV non-small cell lung cancer (NSCLC) patients who could most benefit from the addition of tremelimumab to durvalumab and chemotherapy. ...

BySOPHiA Genetics


Tempus Introduces New HER2 & FOLR1 Testing Solutions to Support Personalized Patient Care

Tempus Introduces New HER2 & FOLR1 Testing Solutions to Support Personalized Patient Care

HER2 and FOLR1 testing by immunohistochemistry (IHC) is now available for all solid tumor cancers as an add-on to the company’s xT or xR next-generation sequencing assays. ADCs are an expanding class of therapies designed to target and kill tumor cells while sparing healthy cells. These very targeted therapies are available to patients ...

ByTempus


Tempus Announces Expansion of Collaboration with AstraZeneca to Leverage Tempus Next to Support Guideline-directed Biomarker Testing in NSCLC

Tempus Announces Expansion of Collaboration with AstraZeneca to Leverage Tempus Next to Support Guideline-directed Biomarker Testing in NSCLC

Tempus, a leader in artificial intelligence and precision medicine, today announces an expansion of its collaboration with AstraZeneca, which leverages Tempus Next to arm physicians with technology that supports the delivery of guideline-directed biomarker testing for patients with non-small cell lung cancer (NSCLC). The magnitude and frequency of updates to ...

ByTempus


Alfa Cytology Launches Full-Scale Preclinical Services for Pancreatic Cancer Research   

Alfa Cytology Launches Full-Scale Preclinical Services for Pancreatic Cancer Research  

Pancreatic cancer (PC) is a severe disease that is difficult to diagnose in the early stages due to its complex and hidden nature. ...

ByAlfa Cytology


Creative Diagnostics Launches New P53 and Tp53 Antibodies for Cancer Research

Creative Diagnostics Launches New P53 and Tp53 Antibodies for Cancer Research

They are present in approximately half of all human malignancies, including breast, colorectal, lung, liver, prostate, bladder and skin cancers. Cancer-associated TP53 gene mutations are primarily missense mutations, which result in the substitution of a single amino acid. ...

ByCreative Diagnostics


CD Genomics Unveils Cutting-Edge 5mC/5hmC Sequencing Service to Drive Epigenomics Research Forward

CD Genomics Unveils Cutting-Edge 5mC/5hmC Sequencing Service to Drive Epigenomics Research Forward

In turn, this empowers researchers to gain a deeper insight into the role of these markers in diverse cell types and biological processes. Why opt for CD Genomics' 5mC/5hmC sequencing service? ...

ByCD Genomics


Carcinotech and CELLINK Enter a Partnership to Develop and Commercialize Protocols for Cancer Models to Provide Improved Speed and Accuracy in the Drug Development Processes

Carcinotech and CELLINK Enter a Partnership to Develop and Commercialize Protocols for Cancer Models to Provide Improved Speed and Accuracy in the Drug Development Processes

Working with patient-derived biopsies, immune cells and cancer stem cells to develop 3D bioprinted Micro-Tumors, Carcinotech has been providing the pharmaceutical sector with crucial services in assisting researchers to optimize drug testing workflows. ...

ByCELLINK


CD Formulation Demonstrates Expertise in CAR-T and CAR-NK Cell Development for Drug Delivery Systems   

CD Formulation Demonstrates Expertise in CAR-T and CAR-NK Cell Development for Drug Delivery Systems  

CAR-T (chimeric antigen receptor T-cell) and CAR-NK (chimeric antigen receptor natural killer cell) therapies involve genetically modifying a patient's own immune cells to recognize and attack cancer cells more efficiently. By engineering these cells to express specific receptors on their ...

ByCD Formulation


CD BioGlyco Announced Service for Analysis of Glycolytic Enzymes in Cancer Cells

CD BioGlyco Announced Service for Analysis of Glycolytic Enzymes in Cancer Cells

CD BioGlyco, a biotechnology company that provides multi-omics analysis of cancer cell glycolysis including genomics, proteomics, metabolomics and metabolic fluxomics, now offers analysis of glycolytic enzymes in cancer cells, enabling thorough understanding of cancer cell glycolysis pathways. ...

ByCD BioGlyco.


Alfa Chemistry Newly Introduces Three APIs to Meet Market Demands: Tofacitinib Citrate, Tamoxifen Citrate, and Epalrestat

Alfa Chemistry Newly Introduces Three APIs to Meet Market Demands: Tofacitinib Citrate, Tamoxifen Citrate, and Epalrestat

Tamoxifen Citrate Tamoxifen Citrate is a medication used to treat breast cancer and prevent its recurrence. It works by blocking the effects of estrogen on breast tissue, which can promote the growth of cancer cells. ...

ByAlfa Chemistry


Bayer to present latest research across its advancing oncology portfolio at AACR 2023 Annual Meeting

Bayer to present latest research across its advancing oncology portfolio at AACR 2023 Annual Meeting

Bayer is progressing novel research around its prostate cancer treatment darolutamide. The presentation highlights the synergistic anti-cancer effects of a PSMA (prostate-specific membrane antigen)-actinium-225 conjugate in combination with darolutamide in preclinical prostate cancer models. Darolutamide, which is jointly developed by Bayer and ...

ByBayer AG


Bayer expands global clinical program for darolutamide in prostate cancer

Bayer expands global clinical program for darolutamide in prostate cancer

Current treatment options for patients with biochemical recurrent prostate cancer include prostatectomy, intending to be curative. If these treatments are unsuccessful, androgen deprivation therapy (ADT) is an option to control disease.2 About darolutamide (Nubeqa) Darolutamide is an oral androgen receptor inhibitor (ARi) with a distinct chemical structure that binds to the ...

ByBayer AG


Nubeqa (darolutamide) approved for additional prostate cancer indication in China

Nubeqa (darolutamide) approved for additional prostate cancer indication in China

In 2020, an estimated 1.4 million men were diagnosed with prostate cancer, and about 375,000 died from the disease worldwide.3 At the time of diagnosis, most men have localized prostate cancer, meaning their cancer is confined to the prostate gland and can be treated with curative surgery or radiotherapy. ...

ByBayer AG


Creative Proteomics Cytokine Boosts Cancer Research with Cancer Cytokines Assay

Creative Proteomics Cytokine Boosts Cancer Research with Cancer Cytokines Assay

Additionally, cancer cells can be responsive to host-derived cytokines, i.e., inducing cancer cell proliferation, attenuating apoptosis, and promoting cellular invasion and metastasis, etc. ...

ByCreative Proteomics


Nubeqa (darolutamide) receives EU approval for additional indication in prostate cancer

Nubeqa (darolutamide) receives EU approval for additional indication in prostate cancer

In 2020, an estimated 1.4 million men were diagnosed with prostate cancer, and about 375,000 died from the disease worldwide.7 At the time of diagnosis, most men have localized prostate cancer, meaning their cancer is confined to the prostate gland and can be treated with curative surgery or radiotherapy. ...

ByBayer AG

  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About Medical XPRT

Medical XPRT is a global marketplace with solutions and suppliers for the medical sector, with product catalogs, articles, industry events, publications & more.

Channels

Solutions

  • Medical XPRT Industry Products
  • Medical XPRT Industry Software
  • Medical XPRT Industry Training
  • Medical XPRT Industry Services
  • Medical XPRT Industry Applications

Latest

  • Medical XPRT Industry News
  • Medical XPRT Industry Events

Publications

  • Medical XPRT Industry Articles
  • Medical XPRT Industry Books
  • Medical XPRT Industry Magazines
  • Medical XPRT Industry Downloads
  • Medical XPRT Industry Videos

Companies

  • Medical XPRT Industry Companies

  • FAQs
  • Company sitemap
  • Category sitemap
Medical XPRT is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • Medical XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
XPRT